Azenta Inc
$ 24.32
-2.53%
16 Apr - close price
- Market Cap 1,120,216,000 USD
- Current Price $ 24.32
- High / Low $ 25.07 / 24.18
- Stock P/E 41.93
- Book Value 37.26
- EPS 0.58
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE 0.02 %
- 52 Week High 41.73
- 52 Week Low 19.87
About
Azenta Inc. is a premier provider of sample management solutions and life science tools, dedicated to enhancing laboratory efficiencies for the biotechnology and pharmaceutical industries. By leveraging innovative automated solutions, comprehensive biorepository services, and advanced storage technologies, the company enables clients to accelerate drug discovery while adhering to stringent regulatory requirements. With a strong emphasis on cutting-edge technology and strategic partnerships, Azenta is well-positioned to seize growth opportunities in the expanding global life sciences market. Its commitment to advancing scientific research through sophisticated products further solidifies its competitive advantage in biobanking and sample management.
Analyst Target Price
$36.17
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-11-11 | 2025-08-05 | 2025-05-07 | 2025-02-05 | 2024-11-12 | 2024-08-06 | 2024-05-08 | 2024-02-07 | 2023-11-13 | 2023-08-08 | 2023-05-09 |
| Reported EPS | 0.09 | 0.21 | 0.19 | 0.05 | 0.08 | 0.18 | 0.16 | 0.05 | 0.02 | 0.13 | 0.13 | -0.06 |
| Estimated EPS | 0.1364 | 0.2 | 0.14 | 0.07 | 0.06 | 0.11 | 0.07 | 0.02 | -0.03 | 0.02 | -0.02 | -0.02 |
| Surprise | -0.0464 | 0.01 | 0.05 | -0.02 | 0.02 | 0.07 | 0.09 | 0.03 | 0.05 | 0.11 | 0.15 | -0.04 |
| Surprise Percentage | -34.0176% | 5% | 35.7143% | -28.5714% | 33.3333% | 63.6364% | 128.5714% | 150% | 166.6667% | 550% | 750% | -200% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.1 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.1 | $0.1 | $0.1 | $0.1 | $0.1 | $0.1 | $0.1 | $0.1 | $0.1 | $0.1 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AZTA
2026-04-16 23:09:41
William E. Martin III, President Multiomics of Azenta, Inc. (AZTA), has filed an initial Form 3 with the SEC, formally recognizing him as a reporting officer of the company. This filing indicates no beneficial ownership or transactions in Azenta securities at the time of submission. The Form 3 establishes his insider status for future reporting requirements.
2026-04-15 21:08:56
This article provides a detailed financial overview of Azenta Inc (BSP:A2ZT34), covering its stock price, key financial metrics, warnings signs, and upcoming events. It highlights the company's business description, financial strength, growth, profitability, and valuation ranks, indicating five good signs detected by GuruFocus despite the company currently operating at a loss. The article also includes news releases and FAQs about Azenta Inc, such as its next earnings date and dividend policy.
2026-04-15 13:08:56
Massachusetts Financial Services Co. MA has made a significant new investment in Azenta, Inc. (NASDAQ:AZTA), purchasing over 1.1 million shares valued at approximately $36.8 million during the fourth quarter, representing about 2.41% ownership. The company's stock currently holds a "Hold" consensus rating from analysts with an average target price of $41.33, following mixed analyst sentiments including price target cuts and varied buy/hold/sell opinions. Azenta reported Q4 EPS of $0.09, missing estimates, but revenue of $148.64 million, slightly exceeding expectations.
2026-04-13 15:40:16
Azenta, Inc. has appointed Trey Martin as President of its Multiomics business, aiming to strengthen its long-term genomics strategy. Martin's extensive experience in scaling genomic platforms is expected to drive the company's Multiomics long-range plan, focusing on synthesis capacity, operations, and commercial execution. This appointment is a key short-term catalyst for Azenta, which aims for significant revenue and earnings growth by 2029, despite ongoing risks in the gene synthesis and sequencing market.
2026-04-09 08:09:50
This article provides a financial overview of Azenta Inc. (AZTA), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company generates 54.0% of its revenue from Sample management solutions, possesses a gross margin of 42.86%, and is benchmarked against industry peers like NEO and PNTG.
2026-04-08 14:40:27
This article provides a precision trading analysis for Azenta Inc. (AZTA) by Stock Traders Daily's Quantitative Research Desk. It presents near-term strong sentiment with neutral mid and long-term outlooks, highlighting elevated downside risk. The analysis includes institutional trading strategies tailored for different risk profiles, such as position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and AI-generated signals for support and resistance levels.
